Scotiabank Has Lowered Expectations for Sarepta Therapeutics (NASDAQ:SRPT) Stock Price

Sarepta Therapeutics (NASDAQ:SRPT) had its target price cut by research analysts at Scotiabank from $105.00 to $80.00 in a research report issued on Thursday,Benzinga reports. The brokerage presently has a “sector perform” rating on the biotechnology company’s stock. Scotiabank’s price target points to a potential upside of 7.96% from the company’s previous close.

SRPT has been the topic of several other research reports. Royal Bank of Canada lowered their price target on Sarepta Therapeutics from $165.00 to $161.00 and set an “outperform” rating on the stock in a research report on Thursday, February 27th. Deutsche Bank Aktiengesellschaft reduced their target price on Sarepta Therapeutics from $124.00 to $99.00 and set a “hold” rating for the company in a research note on Wednesday. HC Wainwright reiterated a “sell” rating and set a $75.00 target price on shares of Sarepta Therapeutics in a research note on Wednesday. StockNews.com downgraded Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, November 20th. Finally, Piper Sandler reduced their target price on Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating for the company in a research note on Wednesday, November 27th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $167.41.

Sarepta Therapeutics Stock Up 0.9 %

Shares of Sarepta Therapeutics stock opened at $74.10 on Thursday. The business’s 50 day simple moving average is $107.19 and its 200 day simple moving average is $118.11. Sarepta Therapeutics has a 52-week low of $73.05 and a 52-week high of $173.25. The firm has a market cap of $7.19 billion, a PE ratio of 59.28 and a beta of 0.79. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84.

Insider Buying and Selling at Sarepta Therapeutics

In other news, Director Claude Nicaise sold 2,491 shares of the business’s stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total transaction of $248,203.24. Following the completion of the transaction, the director now owns 27,812 shares of the company’s stock, valued at approximately $2,771,187.68. The trade was a 8.22 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 7.70% of the company’s stock.

Hedge Funds Weigh In On Sarepta Therapeutics

A number of institutional investors have recently modified their holdings of the business. CIBC Asset Management Inc raised its holdings in shares of Sarepta Therapeutics by 3.3% during the 3rd quarter. CIBC Asset Management Inc now owns 2,712 shares of the biotechnology company’s stock worth $339,000 after buying an additional 86 shares in the last quarter. Louisiana State Employees Retirement System increased its holdings in Sarepta Therapeutics by 0.4% in the 4th quarter. Louisiana State Employees Retirement System now owns 26,500 shares of the biotechnology company’s stock worth $3,222,000 after purchasing an additional 100 shares in the last quarter. EP Wealth Advisors LLC increased its holdings in Sarepta Therapeutics by 2.2% in the 4th quarter. EP Wealth Advisors LLC now owns 4,988 shares of the biotechnology company’s stock worth $606,000 after purchasing an additional 105 shares in the last quarter. Manchester Capital Management LLC increased its holdings in Sarepta Therapeutics by 86.6% in the 4th quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 110 shares in the last quarter. Finally, UMB Bank n.a. increased its holdings in Sarepta Therapeutics by 36.0% in the 4th quarter. UMB Bank n.a. now owns 521 shares of the biotechnology company’s stock worth $63,000 after purchasing an additional 138 shares in the last quarter. Institutional investors and hedge funds own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.